REDWOOD CITY, Calif., Sept. 29, 2016 (GLOBE NEWSWIRE) -- biotricity inc. (OTC.QB:BTCY), a
healthcare technology company dedicated to delivering innovative, medically relevant biometric remote monitoring solutions,
announced today that it will be expanding its existing research partnership with the University of Calgary. In order to develop and
validate the next generation of medically relevant wearable monitors, the focus of the new partnership will be on areas beyond
cardiac medicine including fetal monitoring and sleep apnea. biotricity’s goal is to develop a series of
clinically accurate devices that are applicable in both clinical and home-based settings. The initial focus of this expanded
partnership will be to investigate using Heart Rate Variability Monitoring to optimize recovery after surgery and medical illness,
and to develop solutions for the fetal monitoring and sleep apnea markets as well.
Dr. David Liepert, a clinical assistant professor at the University of Calgary Cumming School of Medicine,
anesthesiologist at AHS’ Rockyview General Hospital and lead investigator of the study adds, “The Department of Anesthesia and
Peri-Operative Medicine looks forward to expanding on the developmental Heart Rate Variability Monitoring (HRVM) work we have
already completed with the bioflux device, and working with biotricity's consumer-based
biolife device as well.”
He explains, “HRVM’s ability to simultaneously monitor internal physiology and activities of daily living combined
with biotricity’s convenience and portability seems ideal for tracking return-to-function and allowing early and
individualized intervention and optimization. Maternal/fetal monitoring has long-included HRVM, and exploring the impact of
offering convenience and portability to that patient group as well as the sleep apnea population is an exciting opportunity. We
look forward to capitalizing on Waqaas Al-Siddiq's expertise in wearable biometric monitoring, connectivity and data processing and
are also exploring the benefits of creating a relationship with the University of Calgary's Schulich School of Engineering which
would be of utmost value to Alberta's budding Biomedical Engineers."
In other news, biotricity is expecting a response from the U.S. Food and Drug Administration (FDA)
to their 510(k) submission within the next few weeks.
biotricity founder and CEO Waqaas Al-Siddiq commented, “We continue to believe a significant
opportunity exists for our remote patient monitoring solutions to gain traction in the rapidly expanding diagnostic and
preventative healthcare markets.”
About Biotricity, Inc.
biotricity is a modern medical technology company focused on delivering innovative, remote
biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic
conditions and lifestyle improvement. biotricity’s R&D continues to focus on the preventative healthcare
market, with a vision of putting health management into the hands of the individual. The company aims to support the
self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the
healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking
statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of
management for future operations, including plans or objectives relating to the design, development and commercialization of
bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including
income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial
items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described
in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans,
objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that
may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from
expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the
significant length of time and resources associated with the development of its products and related insufficient cash flows and
resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical
devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and
litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies.
These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no
obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of
this release.
Media Contacts McCoin & Smith Communications Inc. Chris McCoin, Chris@mccoinsmith.com, 508-429-5988 Richard Smith, rick@mccoinsmith.com, 978-433-3304 Investor Relations: Michael Koehler Liolios Group, Inc. BTCY@liolios.com 949-574-3860
